Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

clipboard-pencil

About the study

The purpose of this study is to evaluate immunogenicity and safety of different doses of candidate hexavalent vaccine in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine(Stage 1) and to demonstrate lot-to-lot consistency of three lots of LBVD (Stage 2)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Infants in stable health
  2. Male or female 6 to 8 weeks of age
  3. Signed informed consent by the infant's parent(s) or legally acceptable representative(s)

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Known or suspected Hib, HepB, diphtheria, tetanus, pertussis, or poliomyelitis
  2. Fever ≥ 38.0℃/100.4℉ within 3 days prior to study registration
  3. Known or suspected immunodeficiency
  4. Previous use of blood or blood-derived products
  5. Previous use of any diphtheria, tetanus, pertussis-based combination vaccine(s), Hib conjugate, poliovirus, or combination
  6. Household contact or intimate exposure with a confirmed case of Hib, HepB, diphtheria, pertussis, tetanus or poliomyelitis within 30 days prior to study registration
  7. Any history of allergy (hypersensitivity) to any of the vaccine components
  8. Participation in another interventional clinical trial simultaneously

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +82-2-3777-1114Email iconEmail Study Center

Study Details


Contition
Diphtheria,Tetanus,Pertussis,Hepatitis B,Poliomyelitis,Haemophilus Influenzae Type B Infection
Age
6 - 8
Phase
PHASE2/PHASE3
Participants Needed
1438
Est. Completion Date
Sep 30, 2025
Treatment Type
INTERVENTIONAL

Sponsor
LG Chem
ClinicalTrials.gov NCT Identifier
NCT05457946
Study Number
LG-VDCL003

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.